FEops, a Belgian cardiovascular-device design company, has selected Dassault Systèmes’ 3DEXPERIENCE SIMULIA application to help evaluate medical devices from the early stages of product development to post-surgical function.
Dassault Systèmes’ 3DEXPERIENCE software will be combined with TAVIguide, FEops’ in-house developed software to help improve the design, planning, safety and efficacy of transcatheter aortic valve implantation (TAVI) products and procedures.
TAVI is a type of minimally invasive heart surgery where a diseased heart valve is replaced with a stent-supported artificial one. The subjectivity of each patient’s anatomy and physical condition means identifying the appropriate size and configuration of a stent valve prior to surgery is critical, as is predicting the performance of the device during implantation and use.
“Cardio- and endo-vascular devices must function in very dynamic environments,” said Matthieu De Beule, Ph.D., co-founder of FEops, part of the IBiTech-bioMMeda group at Ghent University. “Our simulation-based planning tools provide valuable insights for optimal aortic-valve stent device position, size and type. This enables surgeons to make the best pre-operative decisions for their patients and realise the best post-surgical outcomes.”
“In life sciences, as with many other industries, evaluating new ideas by manufacturing prototypes and bench testing them is time-consuming and not always cost-efficient for an enterprise,” said Stephen Chadwick, North Europe managing director, Dassault Systèmes. “Using computer simulation allows exploration of different design alternatives, reduces the amount of real-world prototyping and speeds up product development.”
“This technology will help medical device makers consider a variety of new cardiovascular products in realistic patient anatomies early on in the development cycle,” added De Beule. “TAVIguide also provides additional information useful for regulatory approval, and will help manufacturers better understand the performance of their devices during clinical trials.”
Share this story